Adoptively transferred autologous T lymphocyte (null)

The entry "Cytotoxic activity against disease-associated antigens via adoptively transferred autologous T lymphocytes" does **not** refer to a single molecular target or receptor. Instead, it describes an **immunotherapeutic strategy**—adoptive cell transfer—whereby a patient's own T lymphocytes are isolated, expanded and/or genetically modified ex vivo to enhance their cytotoxic activity against specific disease-related antigens before being reinfused into the patient. This approach includes therapies such as tumor-infiltrating lymphocyte (TIL) therapy and chimeric antigen receptor (CAR) T-cell therapy. These therapies have shown efficacy in certain cancers by enabling the immune system to better recognize and destroy malignant cells expressing particular antigens[1][2][3][5]. However, because this is not a discrete molecular entity but rather an entire therapeutic modality involving living immune cells with variable specificity depending on engineering or selection method, it should not be classified as a canonical drug target. "T-cell transfer therapy is a type of immunotherapy that makes your own immune cells better able to attack cancer... Both involve collecting your own immune cells, growing large numbers of these cells in the lab, and then giving the cells back to you through a needle in your vein." [1] "Adoptive cell transfer... is the transfer of [immune] cells into a patient... In autologous cancer immunotherapy, T-cells are extracted from the patient [and] genetically modified..." [5] Because this entry refers broadly to an approach rather than any one protein/receptor/enzyme/etc., it is considered **incorrect** for use as an individual therapeutic target.

Other names

Adoptive cell transferAutologous T-cell therapyTumor-infiltrating lymphocyte (TIL) therapyCAR T-cell therapyAdoptive immunotherapy[1][5]

Expansion and reinfusion of patient-derived T cells with enhanced ability to recognize and kill disease-associated antigen-expressing cells[1][3]